A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma
Authors:
- 23 August 2008
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 63 (5) , 929-935
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trialBritish Journal of Cancer, 2007
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupSeminars in Oncology, 2003
- Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 HospitalsCancer Research and Treatment, 2002
- Epidemiological Findings of Hepatitis B Infection Based on 1998 National Health and Nutrition Survey in KoreaJournal of Korean Medical Science, 2002
- Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trialThe Lancet, 1998
- Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parametersBritish Journal of Cancer, 1992
- Phase I study of oxaliplatin in patients with advanced cancerCancer Chemotherapy and Pharmacology, 1990
- Hepatocellular carcinoma in Italy: report of a clinical trial with intravenous doxorubicinLiver International, 1985
- Chemotherapy for advanced hepatocellular carcinoma Adriamycin versus quadruple chemotherapyCancer, 1984